Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Arterolane-piperaquine Versus Arterolane-piperaquine+Mefloquine Versus Artemether-lumefantrine in Kenyan Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female aged 2 years to \<13-year-old~2. Uncomplicated falciparum malaria as defined as:~   * Positive blood smear with asexual forms of P. falciparum (may be mixed with non-falciparum species)~  * Parasitaemia between 5,000-250,000 parasites/µL~  * Fever defined as tympanic temperature \>37.5°C or history of fever within last 48 hours~3. Ability to take oral medication~4. Willingness and ability to comply with study protocol for study duration~5. Written informed consent given to participate in the trial~Exclusion Criteria:~1. Signs of severe/complicated malaria\*~2. Any clinical reason suggesting that the child's treatment should be given immediately and not delayed during the transfer to Kilifi County Hospital in the opinion of the treating physician.~3. Acute illness other than malaria requiring urgent systemic treatment as assessed by the treating physician~4. Previous splenectomy~5. Treatment with artemisinin or ACT within the previous 7 days~6. Treatment with mefloquine in the 2 months prior to presentation~7. Known hypersensitivity or contraindication to arterolane-piperaquine, DHA-piperaquine, artemisinin, mefloquine (epilepsy, major psychiatric illness) or primaquine~8. QTc interval \>450 milliseconds at point of presentation~9. Known personal or family history of cardiac conduction problems~10. Participation within another clinical trial in the previous 3 months

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Arterolane-piperaquine (Type: ACTIVE_COMPARATOR): Arterolane-piperaquine for 3 days
- Arterolane-piperaquine+mefloquine (Type: ACTIVE_COMPARATOR): Arterolane-piperaquine + mefloquine for 3 days
- Artemether-lumefantrine (Type: ACTIVE_COMPARATOR): Artemether-lumefantrine for 3 days

Based on this trial design, predict the completion outcome and termination type (if applicable).